QDEL vs. CLDX, NTLA, MYGN, VIVO, HSKA, XRAY, MMSI, HAE, NEOG, and ICUI
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Heska (HSKA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Neogen (NEOG), and ICU Medical (ICUI). These companies are all part of the "medical" sector.
QuidelOrtho (NASDAQ:QDEL) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
In the previous week, QuidelOrtho had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 12 mentions for QuidelOrtho and 5 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.37 beat QuidelOrtho's score of 0.43 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
QuidelOrtho has a net margin of -61.65% compared to Celldex Therapeutics' net margin of -2,385.57%. QuidelOrtho's return on equity of 3.96% beat Celldex Therapeutics' return on equity.
QuidelOrtho has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
QuidelOrtho has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
QuidelOrtho presently has a consensus target price of $59.00, indicating a potential upside of 33.51%. Celldex Therapeutics has a consensus target price of $66.00, indicating a potential upside of 98.20%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than QuidelOrtho.
Celldex Therapeutics received 160 more outperform votes than QuidelOrtho when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 67.28% of users gave QuidelOrtho an outperform vote.
99.0% of QuidelOrtho shares are owned by institutional investors. 1.0% of QuidelOrtho shares are owned by insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Celldex Therapeutics beats QuidelOrtho on 10 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
